Resultados da busca - Frances Collichio

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma por Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman

Obter o texto integral

433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial por Min Yi, Celeste Lebbe, Parminder Singh, Omid Hamid, Jason Chesney, Igor Puzanov, Mohammed Milhem, Merrick Ross, Janice Mehnert, Theodore Logan, Philip Friedlander, Frances Collichio, Claus Garbe, John Glaspy, Axel Hauschild, Wendy Snyder

547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma por Andrew Haydon, Celeste Lebbe, Jose Lutzky, Gregory Daniels, Ragini Kudchadkar, Ann Silk, Nikhil Khushalani, Frances Collichio, Jean-Jaques Grob, Samantha Bowyer, Praveen Bommareddy, Andrew Hill, Danny Rischin, Daniel Brungs, Michael Migden, Matthew Fury, Jenny Lee, Muhammad Alamgeer, Dimitrios Colevas, Wanxing Chai-Ho, Piyush Sheladia, Shui He, Claudia Andreu-Vieyra